Sorrento Therapeutics Inc (SRNE)

[runcaly]

SCILEX & SORRENTO ARE PREPARING FOR SOMETHING REALLY BIG! LOOK WHO'S HIRING!

The Territory Business Manager (TBM) will work in their assigned geography to lead with sales activities. Specifically, the TBM is responsible in their assigned geography to maximize awareness and sales results of promoted products. The TBM will engage key assigned Neurologist, Pain Management and Primary Care Physicians across their assigned territories in face-to-face discussions to promote assigned product(s), maximize the product(s)’ selling potential, meet program objectives, and deliver revenue in an assigned area and contribute to the achievement of the Company’s revenue goals. The TBM will also be responsible to engage key pharmacies in each territory to conduct compliant sales discussions of the products promoted.

So let's look at these new positions that were added. All of these positions are to manage a sales force to maximize promoted products. Which products could they be talking about? ZTlido? PRODUCTS! How many people in the US have shingles? Would they need such a big sales force for shingles? Or are they building the sales force for SP-102? I would believe you would want the sales force all set up and ready to go. So when sp-102 gets the PHASE 3 FDA approval. The team will be ready to go to all the pharmacy's and Physician Offices ready to take the orders.

Territory Business Manager - Denver, CO

https://sorrentotherapeutics.bamboohr.com/jobs/view.php?id=524

Territory Business Manager - Fresno-Bakersfield, CA

https://sorrentotherapeutics.bamboohr.com/jobs/view.php?id=503

Territory Business Manager - Stamford, CT

https://sorrentotherapeutics.bamboohr.com/jobs/view.php?id=454

Regional Team Field Trainer - Internal Position

https://sorrentotherapeutics.bamboohr.com/jobs/view.php?id=493

The Boston Mass position has been filled.

https://investors.sorrentotherapeutics.com/news-releases/news-release-details/scilex-holding-company-sorrento-therapeutics-inc-subsidiary

https://investors.sorrentotherapeutics.com/news-releases/news-release-details/scilex-holding-company-sorrento-company-announces-complete

Scilex Holding Company, a commercial-stage, non-opioid biopharmaceutical pain management company, announced complete enrollment of its SP-102 (SEMDEXA™) Phase 3 Pivotal Trial C.L.E.A.R. Program for its novel, non-opioid, corticosteroid formulation, injectable dexamethasone sodium phosphate viscous gel product for the treatment of lumbosacral radicular pain (sciatica). SP-102 has received Fast Track status from the FDA. Top-line data from the study is expected in Q4 2021.

Chronic pain affects 116 million Americans and costs the U.S. as much as $635 billion each year, according to a recent report from the Institute of Medicine (IOM) that called for changes in how chronic pain is managed6 and nearly 30 million patients suffer from lower back pain in the U.S.8 Government agencies, physicians, patients, and payers are looking for alternatives to opioids to reduce the risk of dependency or addiction, and serious side effects (such as respiratory depression and constipation), while still offering potent solutions for people living with chronic pain.

Know what you own and be patient because THE BEST IS YET TO COME.